Holen Sie sich die Stockscreener-App
3.52
4.61%
-0.17
Ataibeckley Inc Aktie (ATAI) Neueste Nachrichten
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Swings? - simplywall.st
Price to sales ratio of AtaiBeckley Inc. – XETR:B72 - TradingView
AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study - Yahoo Finance
ATAI SEC FilingsAtai Beckley Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AtaiBeckley (FRA:B72) PB Ratio : 5.65 (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting - Insider Monkey
AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study - Finviz
Weighing AtaiBeckley (ATAI) Valuation After Strong One Year Return And Recent Share Price Weakness - Yahoo Finance
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program - TipRanks
AtaiBeckley's BPL-003: Is It a Breakthrough for BTD or a Risky Investment? - Bitget
AtaiBeckley (FRA:B72) Cyclically Adjusted PS Ratio : (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Shiller PE Ratio : (As of Mar. 03, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Cyclically Adjusted Price-to-FCF : (As of Mar. 03, 2026) - GuruFocus
Why AtaiBeckley (ATAI) Is Down 7.3% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
ATAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AtaiBeckley Inc. Share PriceATAI, RNS News, Articles, Quotes, & Charts (NASDAQ:ATAI) - Proactive Investors
AtaiBeckley reports encouraging Phase 2a data for EMP-01 in social anxiety - Proactive financial news
Berenberg Adjusts AtaiBeckley Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
AtaiBeckley to Advance BPL-003 Depression Therapy to Late-Stage Program Following US FDA Meeting - marketscreener.com
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression - Investing News Network
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing - Proactive financial news
AtaiBeckley receives FDA support for depression drug trials - Investing.com
Ataibeckley announces successful end-of-phase 2 meeting for BPL-003 in treatment-resistant depression - marketscreener.com
AtaiBeckley receives FDA support for depression drug trials By Investing.com - Investing.com UK
ATAI Stock Receives Buy Rating with Increased Price Target Today - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety DisorderSlideshow (NASDAQ:ATAI) 2026-02-28 - Seeking Alpha
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial - Yahoo
TD Cowen Conference: ATAI, BCRX, BMRN And More To Present Key Updates - RTTNews
AtaiBeckley Inc. (ATAI): Unpacking The 233.90% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial - TipRanks
AtaiBeckley reports positive Phase 2a trial results for EMP-01 By Investing.com - Investing.com Canada
[144] Atai Beckley N.V. SEC Filing - Stock Titan
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 in Social Anxiety Disorder - Investing News Network
Small cap wrap: Northstar Gold, AtaiBeckley, Alvopetro Energy, C3 Metals… - Proactive Investors
R-MDMA phase II cheers up Ataibeckley in SAD - bioworld.com
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug - Endpoints News
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial - Proactive Investors
AtaiBeckley's Phase 2a Study Of EMP 01 In Social Anxiety Disorder Meets Key Goal - Nasdaq
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - Bitget
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results - Investing.com India
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results By Investing.com - Investing.com Nigeria
AtaiBeckley reports positive Phase 2a trial results for EMP-01 - Investing.com
Experimental MDMA pill eases severe social anxiety in early AtaiBeckley trial - Stock Titan
A Look At AtaiBeckley (ATAI) Valuation After Virtual Investor Day Announcement And Strong Recent Returns - simplywall.st
AtaiBeckley’s Contradictory Indicators: Rising Cash Meets Negative Chart Trends - Bitget
JonesTrading Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
AtaiBeckley CFO Change Puts Funding And Dilution In Sharper Focus - simplywall.st
Why AtaiBeckley (ATAI) Is Up 11.2% After CFO Transition And Virtual Investor Day Announcement - Yahoo Finance
Does AtaiBeckley’s (ATAI) CFO Shuffle Reveal a New Financial Strategy for Its Mental Health Pipeline? - simplywall.st
AtaiBeckley announces Virtual Investor Day on March 6 - Proactive financial news
AtaiBeckley Inc. (ATAI): Biotech Disruptor with a Promising 226% Upside Amid Mental Health Breakthroughs - DirectorsTalk Interviews
4.16%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):